↑ 薬物リストへ　← 戻る

Reslizumab    (DrugBank: Reslizumab)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
44多発血管炎性肉芽腫症1
98好酸球性消化管疾患2

44. 多発血管炎性肉芽腫症　［臨床試験数：84，薬物数：88（DrugBank：22），標的遺伝子数：13，標的パスウェイ数：37］
Searched query = "Wegener granulomatosis", "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 84 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02947945
(ClinicalTrials.gov)		September 12, 201717/10/2016Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyOpen-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE StudyAsthmaDrug: ReslizumabNational Jewish HealthTEVARecruiting18 YearsN/AAll10Phase 2United States

98. 好酸球性消化管疾患　［臨床試験数：128，薬物数：147（DrugBank：40），標的遺伝子数：34，標的パスウェイ数：132］
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00635089
(ClinicalTrials.gov)		July 20086/3/2008Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic EsophagitisAn Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002Eosinophilic EsophagitisDrug: reslizumabCeption TherapeuticsCephalonCompleted5 YearsN/AAll190Phase 3United States;Canada
2NCT00538434
(ClinicalTrials.gov)		March 20081/10/2007Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsAn Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 YearsEosinophilic EsophagitisBiological: Reslizumab;Other: SalineCeption TherapeuticsNULLCompleted5 Years18 YearsAll227Phase 2;Phase 3United States;Canada